Their analysis, which included 708 cases of women with contralateral breast cancer and 1,399 controls with unilateral breast cancer, found that carriers of ATM pathogenic variants showed a small but not statistically significant increase in contralateral breast cancer risk (RR = 1.68, 95% CI = 0.75–3.76, p = 0.20). Here, ATM is linked to breast carcinoma.